Dorsey Wright & Associates purchased a new position in GW Pharmaceuticals PLC- (NASDAQ:GWPH) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 41,134 shares of the biopharmaceutical company’s stock, valued at approximately $7,106,000. GW Pharmaceuticals PLC- comprises about 1.3% of Dorsey Wright & Associates’ holdings, making the stock its 20th largest holding. Dorsey Wright & Associates owned about 0.15% of GW Pharmaceuticals PLC- at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of the stock. Flagship Harbor Advisors LLC bought a new stake in GW Pharmaceuticals PLC- during the second quarter valued at $109,000. Envestnet Asset Management Inc. bought a new stake in GW Pharmaceuticals PLC- during the second quarter valued at $119,000. WealthTrust Fairport LLC bought a new stake in GW Pharmaceuticals PLC- during the first quarter valued at $104,000. Cowen Prime Services LLC increased its stake in GW Pharmaceuticals PLC- by 708.0% during the second quarter. Cowen Prime Services LLC now owns 1,010 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 885 shares during the last quarter. Finally, BNP Paribas Arbitrage SA increased its stake in GW Pharmaceuticals PLC- by 497.0% during the second quarter. BNP Paribas Arbitrage SA now owns 1,200 shares of the biopharmaceutical company’s stock valued at $167,000 after purchasing an additional 999 shares during the last quarter. Institutional investors and hedge funds own 75.44% of the company’s stock.
Several analysts have weighed in on the stock. Bank of America reiterated a “buy” rating and set a $197.00 target price (up previously from $181.00) on shares of GW Pharmaceuticals PLC- in a research note on Friday, September 28th. Morgan Stanley boosted their target price on shares of GW Pharmaceuticals PLC- from $197.00 to $240.00 and gave the company an “overweight” rating in a research note on Friday, September 28th. Cantor Fitzgerald set a $211.00 target price on shares of GW Pharmaceuticals PLC- and gave the company a “buy” rating in a research note on Thursday, September 27th. BidaskClub upgraded shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a research note on Saturday, September 22nd. Finally, Zacks Investment Research upgraded shares of GW Pharmaceuticals PLC- from a “hold” rating to a “strong-buy” rating and set a $168.00 target price for the company in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $185.00.
GWPH stock traded up $2.36 during trading on Friday, hitting $143.32. 470,600 shares of the company’s stock traded hands, compared to its average volume of 447,557. GW Pharmaceuticals PLC- has a 52 week low of $101.07 and a 52 week high of $179.65. The firm has a market cap of $4.80 billion, a price-to-earnings ratio of -20.82 and a beta of 2.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.67 and a quick ratio of 8.21.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.40) by $1.14. GW Pharmaceuticals PLC- had a negative net margin of 1,392.61% and a negative return on equity of 47.65%. The company had revenue of $3.46 million during the quarter, compared to the consensus estimate of $2.00 million. As a group, analysts expect that GW Pharmaceuticals PLC- will post -9.11 EPS for the current fiscal year.
GW Pharmaceuticals PLC- Profile
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.
Further Reading: Return on Investment (ROI) Defined, Explained
Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC- (NASDAQ:GWPH).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.